NewAmsterdam Pharma Subsidiary Secures Supply Agreement with Menarini for Obicetrapib Products

Reuters

08/16

NewAmsterdam Pharma Subsidiary Secures Supply Agreement with Menarini for Obicetrapib Products

NewAmsterdam Pharma Company NV recently announced a significant development with its subsidiary, NewAmsterdam Pharma B.V., entering into a Supply Agreement with A. Menarini International Licensing S.A. This agreement, following the License Agreement from June 2022, designates the subsidiary as the exclusive supplier of obicetrapib monotherapy and a fixed-dose combination of obicetrapib and ezetimibe to Menarini. The supply will be based on volume forecasts provided by Menarini, with pricing determined by a specified mark-up on the cost of goods sold. The agreement outlines a future transfer of drug manufacturing to Menarini or a designated third-party manufacturer, with a non-exclusive license granted for the manufacturing process. The Supply Agreement is set to last as long as the License Agreement continues, with provisions for termination under certain conditions. This strategic partnership marks a pivotal step in the expansion of NewAmsterdam Pharma's market presence.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-109387), on August 15, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2559450749"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559450749\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559450749?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-16 04:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559450749","market":"fut","top_or_hot":-1,"title":"NewAmsterdam Pharma Subsidiary Secures Supply Agreement with Menarini for Obicetrapib Products","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NewAmsterdam Pharma Subsidiary Secures Supply Agreement with Menarini for Obicetrapib Products\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NewAmsterdam Pharma Company NV recently announced a significant development with its subsidiary, NewAmsterdam Pharma B.V., entering into a Supply Agreement with A. Menarini International Licensing S.A. This agreement, following the License Agreement from June 2022, designates the subsidiary as the exclusive supplier of obicetrapib monotherapy and a fixed-dose combination of obicetrapib and ezetimibe to Menarini. The supply will be based on volume forecasts provided by Menarini, with pricing determined by a specified mark-up on the cost of goods sold. The agreement outlines a future transfer of drug manufacturing to Menarini or a designated third-party manufacturer, with a non-exclusive license granted for the manufacturing process. The Supply Agreement is set to last as long as the License Agreement continues, with provisions for termination under certain conditions. This strategic partnership marks a pivotal step in the expansion of NewAmsterdam Pharma's market presence.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-109387), on August 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NewAmsterdam Pharma Subsidiary Secures Supply Agreement with Menarini for Obicetrapib Products</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNewAmsterdam Pharma Subsidiary Secures Supply Agreement with Menarini for Obicetrapib Products\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-16 04:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NewAmsterdam Pharma Subsidiary Secures Supply Agreement with Menarini for Obicetrapib Products\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NewAmsterdam Pharma Company NV recently announced a significant development with its subsidiary, NewAmsterdam Pharma B.V., entering into a Supply Agreement with A. Menarini International Licensing S.A. This agreement, following the License Agreement from June 2022, designates the subsidiary as the exclusive supplier of obicetrapib monotherapy and a fixed-dose combination of obicetrapib and ezetimibe to Menarini. The supply will be based on volume forecasts provided by Menarini, with pricing determined by a specified mark-up on the cost of goods sold. The agreement outlines a future transfer of drug manufacturing to Menarini or a designated third-party manufacturer, with a non-exclusive license granted for the manufacturing process. The Supply Agreement is set to last as long as the License Agreement continues, with provisions for termination under certain conditions. This strategic partnership marks a pivotal step in the expansion of NewAmsterdam Pharma's market presence.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-109387), on August 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250815:nNDL7jHYN2:1","article_id":"2559450749","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559450749","pubTimestamp":1755288401,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NewAmsterdam Pharma Company NV recently announced a significant development with its subsidiary, NewAmsterdam Pharma B.V., entering into a Supply Agreement with A. Menarini International Licensing S.A. This agreement, following the License Agreement from June 2022, designates the subsidiary as the exclusive supplier of obicetrapib monotherapy and a fixed-dose combination of obicetrapib and ezetimibe to Menarini. The supply will be based on volume forecasts provided by Menarini, with pricing determined by a specified mark-up on the cost of goods sold. The agreement outlines a future transfer of drug manufacturing to Menarini or a designated third-party manufacturer, with a non-exclusive license granted for the manufacturing process. The Supply Agreement is set to last as long as the License Agreement continues, with provisions for termination under certain conditions. This strategic partnership marks a pivotal step in the expansion of NewAmsterdam Pharma's market presence.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NAMS":"NEWAMSTERDAM PHARMA CO NV"},"translate_title":"NewAmsterdam Pharma子公司与Menarini签订Obicetrapib产品供应协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NAMS":0.9},"content_text":"NewAmsterdam Pharma Subsidiary Secures Supply Agreement with Menarini for Obicetrapib Products\n    \n\n        NewAmsterdam Pharma Company NV recently announced a significant development with its subsidiary, NewAmsterdam Pharma B.V., entering into a Supply Agreement with A. Menarini International Licensing S.A. This agreement, following the License Agreement from June 2022, designates the subsidiary as the exclusive supplier of obicetrapib monotherapy and a fixed-dose combination of obicetrapib and ezetimibe to Menarini. The supply will be based on volume forecasts provided by Menarini, with pricing determined by a specified mark-up on the cost of goods sold. The agreement outlines a future transfer of drug manufacturing to Menarini or a designated third-party manufacturer, with a non-exclusive license granted for the manufacturing process. The Supply Agreement is set to last as long as the License Agreement continues, with provisions for termination under certain conditions. This strategic partnership marks a pivotal step in the expansion of NewAmsterdam Pharma's market presence.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-109387), on August 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}